172 related articles for article (PubMed ID: 22246526)
1. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.
Hongo K; Kazama S; Sunami E; Tsuno NH; Takahashi K; Nagawa H; Kitayama J
Med Oncol; 2012 Dec; 29(4):2849-57. PubMed ID: 22246526
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
4. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
5. CD133: a cancer stem cells marker, is used in colorectal cancers.
Ren F; Sheng WQ; Du X
World J Gastroenterol; 2013 May; 19(17):2603-11. PubMed ID: 23674867
[TBL] [Abstract][Full Text] [Related]
6. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
[TBL] [Abstract][Full Text] [Related]
8. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
9. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
10. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
11. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
12. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
14. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
18. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
[TBL] [Abstract][Full Text] [Related]
20. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients.
Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK
J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
